131I-Metaiodobenzylguanidine Therapy of Pheochromocytoma

131I-间碘苄胍治疗嗜铬细胞瘤

• 批准号: 6813962
• 负责人: Karel Pacak
• 金额: --
• 依托单位: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6813962
• 关键词: catecholamines; chemosensitizing agent; chromaffin cells; guanidines; human subject; human therapy evaluation; iodine; neoplasm /cancer radionuclide therapy; patient oriented research; phenylethylamines; pheochromocytoma; radionuclides

Pheochromocytomas are tumors of chromaffin cells that synthesize and secrete catecholamines. This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-metaiodobenzylguanidine (131I-MIBG), and in particular tests whether pre-treatment using specific drugs (so called sentitizers) increases the efficacy of 131I-MIBG treatment in reducing the size and number of tumors and the tumor burden. The central hypothesis is that in patients with malignant pheochromocytoma, treatment with 131I-MIBG destroys tumor cells and thereby decreases the size and number of tumors and the tumor burden; and that the "sensitization" procedures augment the effectiveness of 131I-MIBG. This new protocol still needs some clarifications from the FDA, therefore, no patients have been enrolled into the study so far.

嗜铬细胞瘤是合成和分泌儿茶酚胺的嗜铬细胞的肿瘤。该项目测试使用131 I-间碘苄胍（131 I-MIBG）放射毒性治疗恶性嗜铬细胞瘤的疗效，特别是测试使用特定药物（所谓的增敏剂）的预治疗是否增加131 I-MIBG治疗在减少肿瘤大小和数量以及肿瘤负荷方面的疗效。中心假设是，在恶性嗜铬细胞瘤患者中，用131 I-MIBG治疗破坏肿瘤细胞，从而减少肿瘤的大小和数量以及肿瘤负荷;并且“致敏”程序增加了131 I-MIBG的有效性。这项新方案仍需要FDA的一些澄清，因此，迄今为止尚未有患者入组研究。